CONGRESS NEWS

Highlights in indolent non-hodgkin lymphoma and diffuse large B-cell lymphoma

SUMMARY

As usual, June was a very busy month for lymphoma specialists, with back to back, international meetings. This report will summarize some key data related to non-hodgkin lymphoma, presented during the 2017 International Conference on Malignant Lymphoma (ICML; Lugano June 14–17) and the 2017 annual meeting of the European Hematology Association (EHA; Madrid June 22–25). We would like to acknowledge Prof Ann Janssens (University Hospital Leuven) for her help in selecting the abstracts presented here.

(BELG J HEMATOL 2017;8(4):158–64)

Highlights in thrombosis and inherited platelet disorders

(BELG J HEMATOL 2017;8(4):166–7)

Highlights in acute myeloid leukemia

SUMMARY

With the unraveling of the molecular basis of AML last year, new treatment options have arisen and new insights were established concerning disease response to therapy, its impact on prognosis and its relevance for post-remission treatment decisions.

(BELG J HEMATOL 2017;8(4):171–5)

European Society for Blood and Marrow Transplantation (EBMT) 43^rd Annual Meeting

SUMMARY

The 43^rd annual meeting of the European Society for Blood and Marrow Transplantation took place in Marseille between March 26^th and March 29^th, 2017. The society celebrated 60 years of history in the field of hematopoietic stem cell transplantation. This report summarises some interesting abstracts that were presented during the meeting.

(BELG J HEMATOL 2017;8(3):122–4)

Biosimilars in the Belgian health care plan

(BELG J HEMATOL 2017;8(2):87–8)

Highlights in multiple myeloma

SUMMARY

Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment modalities, alongside optimization of those already available, boldly continues. Each year, the ASH congress offers us the opportunity to learn about the latest developments in the MM field. This text aims to provide a brief summary of some of the latest insights presented at ASH this year.

(BELG J HEMATOL 2017;8(1):3–7)

Highlights in aggressive lymphoma

SUMMARY

ASH 2016 again featured a plethora of abstracts dedicated to lymphoma. In this summary we will discuss the studies that, in our opinion, have the highest relevance for daily clinical practice. This summary will not address indolent lymphoma as this will be covered in another article in this ASH special.

(BELG J HEMATOL 2017;8(1):10–3)